Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of JW0061 Following Topical Application in Healthy Adults
NCT07514780Phase 1Recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JW0061 in alopecia (4 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Treatment-Emergent Adverse Events at Day 28, Skin Irritation Assessment - Subjective at Day 28 and 8 more. Started Apr 2026; status: recruiting.
02
Drugs
JW0061
03
Conditions
alopecia
Beyond the preview
Go deeper on NCT07514780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514780.